ArticleAmerican journal of hematology2012
Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.
Article in American journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.Annals of internal medicine · 2018Pooled it
- Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.JAMA · 2014Pooled it
- Characterizing Metabolic and Compositional Heterogeneity of Calf Muscle Using CEST MRI at 3 T.NMR in biomedicine · 2026Article
- Carrier screening in the reproductive setting-Are there medical implications for the heterozygote?-A guide for clinicians.Pregnancy (Hoboken, N.J.) · 2026Review
- Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap.Trauma surgery & acute care open · 2022Article
- The Alberta Newborn Screening Approach for Sickle Cell Disease: The Advantages of Molecular Testing.International journal of neonatal screening · 2021Article
- Sickle cell trait newborn screen results: disclosure and management.Journal of community genetics · 2021Article
- Review
- Pregnancy in sickle cell trait: what we do and don't know.British journal of haematology · 2020Review
- 5-(Hydroxymethyl)furfural restores low-oxygen rheology of sickle trait blood in vitro.British journal of haematology · 2020Article
- Hemoglobinopathies and Hemoglobin A1c in Diabetes Mellitus.Journal of diabetes science and technology · 2020Article
- The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2020Review
- Sickle cell carriers' unmet information needs: Beyond knowing trait status.Journal of genetic counseling · 2019Article
- Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin.Blood advances · 2019Article
- The indirect health effects of malaria estimated from health advantages of the sickle cell trait.Nature communications · 2019Article
- [Case study of acute thoracic syndrome of unknown etiology in a pregnant woman].The Pan African medical journal · 2019Article
- Identifying Factors Underlying the Decision for Sickle Cell Carrier Screening Among African Americans Within Middle Reproductive Age.Journal of genetic counseling · 2018Article
- Sickle Cell Trait and Sudden Death.Sports medicine - open · 2018Review
- GBT440 Inhibits Sickling of Sickle Cell Trait Blood UnderHematology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
Sickle Cell Trait (HbAS), the heterozygous state for the sickle hemoglobin beta globin gene is carried by as many as 100 million individuals including up to 25% of the population in some regions of the world (World Health Organization, Provisional agenda item 4.8, EB117/34 (22 December 2005) or World Health Organization, Provisional agenda item 11.4 (24 April 2006)). Persons with HbAS have some resistance to falciparum malaria infection in early childhood (Piel FB, Patil AP, Howes RE, et al., Nat Commun 2010;1104:1-7 and Aidoo M, Terlouw DJ, Kolczak M, et al., Lancet 2002;359:1311-1312) and as a result individuals with HbAS living in malarial endemic regions of Africa have a survival advantage over individuals with HbAA. Reports from the US emphasize possible health risks for individuals with HbAS including increased incidence of renal failure and malignancy, thromboembolic disorders, splenic infarction as a high altitude complication, and exercise-related sudden death. The National Heart, Lung, and Blood Institute, National Institutes of Health convened a workshop in Bethesda, Maryland on June 3-4, 2010, Framing the Research Agenda for Sickle Cell Trait, to review the clinical manifestations of HbAS, discuss the exercise-related sudden death reports in HbAS, and examine the public health, societal, and ethical implications of policies regarding HbAS. The goal of the workshop was to identify potential research questions to address knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.